Latest Period
Q2 2026
Security Snapshot
FATE THERAPEUTICS INC - Common Stock (FATE) Institutional Ownership
CUSIP: 31189P102
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
155
Shares (Excl. Options)
71,550,170
Price
$2.70
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- FATE on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 71,550,170
- Total 13F value
- $193,103,900
- Portfolio coverage rank
- 0%
- Share change
- -2,584,967
- Value change
- -$715,433
- Number of holders
- 155
- Shares outstanding
- 115,488,632
- SEC-reported price per share
- $2.41
- Insider filing price
- $2.41
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- FATE - FATE THERAPEUTICS INC - Common Stock is tracked under CUSIP 31189P102.
- 155 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 156 to 155 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $88,883,087 to $193,103,900.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 155 institutions filings for Q2 2026.
Security key
31189P102
Latest holder period
Q2 2026
13F holders
155
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
FATE full holder history
FATE THERAPEUTICS INC SEC filings
FATE THERAPEUTICS INC company facts
FATE THERAPEUTICS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 31189P102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
FATE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 15% | 0% | $21,874,894 | +$344,999 | 18,229,078 | +1.6% | Redmile Group, LLC | 20 Apr 2026 |
| GOLDMAN SACHS GROUP INC | 2% | -77% | $2,546,902 | -$6,958,784 | 2,274,020 | -73% | THE GOLDMAN SACHS GROUP, INC. | 30 Jun 2025 |
| BlackRock, Inc. | 1.9% | -71% | $5,924,786 | -$15,276,893 | 2,194,284 | -72% | BlackRock, Inc. | 30 Jun 2026 |
| Schonfeld Strategic Advisors LLC | 0.82% | -85% | $1,050,024 | -$7,679,831 | 937,521 | -88% | Schonfeld Strategic Advisors LLC | 30 Jun 2025 |
As of 30 Jun 2026, 155 institutional investors reported holding 71,550,170 shares of FATE THERAPEUTICS INC - Common Stock (FATE). This represents 62% of the company’s total 115,488,632 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
54%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Redmile Group, LLC | 11% | 12,872,946 | 0% | 2.3% | $34,756,954 |
| BlackRock, Inc. | 6.3% | 7,298,895 | -28% | 0% | $19,707,016 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.9% | 4,545,893 | +9.9% | 0% | $12,273,911 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 4,445,536 | +6% | 0% | $12,002,947 |
| ACADIAN ASSET MANAGEMENT LLC | 3.8% | 4,351,250 | +5.6% | 0.01% | $11,742,000 |
| AQR CAPITAL MANAGEMENT LLC | 3.3% | 3,837,229 | +28% | 0% | $10,360,518 |
| TWO SIGMA INVESTMENTS, LP | 3.1% | 3,589,863 | +3.6% | 0.01% | $9,692,630 |
| JOHNSON & JOHNSON | 2.9% | 3,379,064 | 0% | 1.1% | $9,123,473 |
| RENAISSANCE TECHNOLOGIES LLC | 2.6% | 2,983,268 | +0.29% | 0.01% | $8,054,824 |
| MILLENNIUM MANAGEMENT LLC | 2.1% | 2,433,978 | 0% | $6,571,741 | |
| GOLDMAN SACHS GROUP INC | 1.8% | 2,049,187 | +54% | 0% | $5,532,805 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 1,322,013 | -49% | 0% | $3,571,058 |
| T. Rowe Price Investment Management, Inc. | 0.94% | 1,080,320 | 0% | $2,917,000 | |
| JANE STREET GROUP, LLC | 0.89% | 1,027,007 | +59% | 0% | $2,772,919 |
| CITADEL ADVISORS LLC | 0.86% | 993,308 | +5.3% | 0% | $2,681,931 |
| Bruce & Co., Inc. | 0.86% | 989,188 | +25% | 0.72% | $2,670,808 |
| MORGAN STANLEY | 0.6% | 694,580 | -9.5% | 0% | $1,875,366 |
| VANGUARD FIDUCIARY TRUST CO | 0.55% | 640,428 | -2% | 0% | $1,729,156 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.53% | 610,949 | -19% | 0% | $1,649,562 |
| UBS Group AG | 0.51% | 590,178 | -68% | 0% | $1,593,481 |
| Qube Research & Technologies Ltd | 0.5% | 578,150 | 0% | $1,561,005 | |
| Connor, Clark & Lunn Investment Management Ltd. | 0.5% | 574,995 | +22% | 0% | $1,552,487 |
| STATE STREET CORP | 0.48% | 558,928 | -75% | 0% | $1,509,106 |
| DAFNA Capital Management LLC | 0.45% | 525,000 | -4.5% | 0.27% | $1,417,500 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.44% | 511,050 | +71% | 0% | $1,379,835 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 71,550,170 | $193,103,900 | -$715,433 | $2.70 | 155 |
| 2026 Q1 | 74,105,799 | $88,883,087 | +$3,284,142 | $1.20 | 156 |
| 2025 Q4 | 72,135,207 | $70,931,982 | -$11,120,163 | $0.98 | 145 |
| 2025 Q3 | 80,446,666 | $101,355,707 | +$1,878,808 | $1.26 | 138 |
| 2025 Q2 | 79,555,724 | $88,833,451 | -$17,593,195 | $1.12 | 136 |
| 2025 Q1 | 96,451,503 | $76,210,377 | -$16,246,755 | $0.79 | 127 |
| 2024 Q4 | 100,742,490 | $166,216,764 | -$49,322,737 | $1.65 | 154 |
| 2024 Q3 | 114,626,757 | $401,134,107 | -$26,268,311 | $3.50 | 157 |
| 2024 Q2 | 122,159,363 | $400,671,566 | -$37,762,295 | $3.28 | 176 |
| 2024 Q1 | 122,980,750 | $902,678,660 | +$225,457,297 | $7.34 | 160 |
| 2023 Q4 | 95,368,059 | $356,677,597 | -$5,241,221 | $3.74 | 152 |
| 2023 Q3 | 95,698,313 | $202,876,531 | -$41,469,527 | $2.12 | 164 |
| 2023 Q2 | 109,140,532 | $519,540,682 | -$18,388,551 | $4.76 | 183 |
| 2023 Q1 | 112,556,300 | $641,545,712 | -$48,046,056 | $5.70 | 177 |
| 2022 Q4 | 105,538,752 | $1,064,884,147 | -$72,227,908 | $10.09 | 222 |
| 2022 Q3 | 107,847,419 | $2,414,270,747 | -$51,535,763 | $22.41 | 226 |
| 2022 Q2 | 109,105,314 | $2,682,160,938 | +$198,082,382 | $24.78 | 212 |
| 2022 Q1 | 101,146,307 | $3,918,572,903 | +$154,288,770 | $38.77 | 235 |
| 2021 Q4 | 96,474,919 | $5,644,897,783 | +$10,118,846 | $58.51 | 240 |
| 2021 Q3 | 95,702,027 | $5,670,584,893 | +$32,917,992 | $59.27 | 254 |
| 2021 Q2 | 94,438,853 | $8,194,463,579 | +$63,508,082 | $86.79 | 264 |
| 2021 Q1 | 93,763,343 | $7,731,987,612 | +$546,947,235 | $82.45 | 251 |
| 2020 Q4 | 87,411,381 | $7,948,482,716 | -$84,784,180 | $90.93 | 247 |
| 2020 Q3 | 87,813,890 | $3,509,314,003 | +$84,938,020 | $39.97 | 210 |
| 2020 Q2 | 85,944,579 | $2,946,905,994 | +$357,311,792 | $34.31 | 199 |